Clinical Research

Found 142,651 articles

• Virogentics Inc. Announces Pilot Clinical Trial of ITV-1 at National Center for Endocrinology in Bulgaria and Expansion of Nutraceutical Line

  5/8/2023

  Enzolytics, Inc. announced that the Company's wholly owned subsidiary, Virogenetics (VIRO), will be conducting a pilot clinical trial test for the state owned Bulgarian National Center for Endocrinology to gauge the effectiveness of the ITV-1 immunotherapy on Diabetes.

• Solarea Bio Announces First Close of Series B Financing Round

  5/8/2023

  Solarea Bio announced today a first closing of $15m in a Series B financing led by S2G Ventures with continued participation of Bold Capital Partners, Viking Global Investors, and GG 1978 SICAF SIF.

• New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023

  5/8/2023

  INOVIO presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

• Temple Therapeutics Reveals Breakthrough Findings on Ovarian Cancer at AACR 2023

  5/8/2023

  Temple Therapeutics presented new in vitro and in vivo data on TTX335o, the first drug candidate from the company’s platform that won the Eurostar Eureka peer-reviewed grant process in 2019 for ovarian cancer.

• Life Biosciences and Forge Biologics Announce cGMP Manufacturing Partnership to Advance Development of Novel Gene Therapies for Aging-Related Diseases

  5/8/2023

  Life Biosciences and Forge Biologics today announced a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.

• Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting

  5/8/2023

  Natera, Inc. today announced the publication of a new paper 1 in Cancer Cell from the I-SPY2 trial, highlighting the prognostic and predictive utility of Natera’s personalized and tumor-informed, molecular residual disease (MRD) test, Signatera, in locally advanced breast cancer patients receiving neoadjuvant chemotherapy (NAC, treatment before surgery).

• Scholar Rock to Present New Data Evaluating Apitegromab at 36 Months from the Phase 2 TOPAZ trial at the 2023 Annual Cure SMA Conference

  5/8/2023

  Scholar Rock announced today it will present extension data from the Phase 2 TOPAZ trial evaluating patient outcomes after 36 months of treatment with apitegromab.

• Viatris Reports Strong Financial and Operational Results for First Quarter 2023 and Reaffirms Full-Year 2023 Guidance Ranges[1]

  5/8/2023

  Viatris Inc. (NASDAQ: VTRS) today reported strong results for the first quarter of 2023 reflecting another robust operational performance and instilling further confidence in the Company's ability to return to growth as it prepares to enter Phase 2 of its strategic plan in 2024.

• Chance Pharmaceuticals and Acorda Therapeutics Announce Agreement to Provide INBRIJA® in Greater China

  5/8/2023

  Chance Pharmaceuticals and Acorda Therapeutics, Inc. today announced that they have entered into distribution and supply agreements to provide INBRIJA ® in Greater China (Mainland China , Taiwan , Hong Kong , and Macao ). INBRIJA is indicated in the United States for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.

• Insmed Unveils New Research Platforms and Capabilities at Investor and Analyst Event, "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More"

  5/8/2023

  Insmed Incorporated today announced progress across its early-stage research programs, which will be discussed in greater detail this morning at the Company's investor and analyst event, The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More.

• Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week® 2023

  5/8/2023

  Ironwood Presents New Data on Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old at Digestive Disease Week ® 2023.

• Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025

  5/8/2023

  Acasti Pharma Inc. today announced the successful submission to the FDA of GTX-104's full protocol of its pivotal Phase 3 Safety Study and implementation of a strategic realignment plan to maximize shareholder value.

• CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK

  5/8/2023

  CureVac N.V. today announced that the first participant was dosed in the Phase 1 part of a combined Phase 1/2 study of multivalent, modified mRNA seasonal flu vaccine candidates, developed in collaboration with GSK.

• Ginkgo Bioworks Partners with Boehringer Ingelheim to Develop Breakthrough Therapies for Hard-to-Treat Diseases

  5/8/2023

  Ginkgo Bioworks today announced a new partnership with Boehringer Ingelheim.

• Genome Insight Launches in the U.S. with Innovative Whole Genome Sequencing Approach that Offers Unprecedented, Actionable Insights in Cancer Care

  5/8/2023

  Genome Insight announced today the U.S. launch of CancerVision, their innovative whole genome sequencing (WGS) test designed to provide accurate, timely and medically meaningful insights that collectively guide personalized healthcare decisions.

• Innovent Updates the Results from the ORIENT-31 Study of Sintilimab Plus Chemotherapy With or Without Bevacizumab in Patients with EGFR-TKI failed EGFR-mutated Non-Squamous Non-Small Cell Lung Cancer in the Lancet Respiratory Medicine

  5/8/2023

  Innovent Biologics, Inc. announces that second interim analysis and survival analysis results of the ORIENT-31 study have been published in the Lancet Respiratory Medicine.

• Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week

  5/8/2023

  Vedanta Biosciences today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Vedanta’s defined bacterial consortium candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (rCDI).

• SomaLogic opens their first-ever proteomics grant program to APAC life sciences researchers

  5/8/2023

  SomaLogic, Inc., a global leader in proteomics technology, announced that it is sponsoring the Genomax Research Grant Award for researchers in Singapore.

• Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease

  5/8/2023

  Innovent Biologics, Inc. announces that the first patient with Thyroid Eye Disease has been successfully dosed in the Phase 3 study of IBI311, a recombinant anti-insulin-like growth factor-1 receptor monoclonal antibody.

• Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions

  5/8/2023

  Bruker Announces Acquisition of ZONTAL to Advance the Digital Laboratory Transformation and Integrated Biopharma Data Solutions.